INNOVADERM CRO IS NOW INDERO.

Urticaria Case Study

Indero

Indero

Team of Experts

Author picture

Click here for a PDF version of this case study

Outcomes

Indero successfully rescued this urticaria study and this resulted in:

Recruitment on Time

The study was completed successfully, demonstrating Indero’s ability to manage early phase international clinical trials.

Client Feedback

“We have had strong project director support which contributed to the successful collaboration between the client and Indero. Our concerns and issues were heard and addressed in a timely manner.

 

Study Details

  • Phase: Ib
  • Indication: CIndU (Cold urticaria or Symptomatic dermographism)
  • Sites Location: Germany (4), Netherlands (1), Spain (2), Canada & USA (9)
  • Blinding: Open Label

Active Collaboration

  • Strong Relationship with Charité: The collaboration with Charité and Dr. Metz was instrumental in achieving the study’s objectives.
  • Successful IM in Berlin: High engagement from the sites and excellent representation from across Europe.

 

Challenges & Solutions

  • Seasonality: Despite key recruitment period over warmer months with reduced prominence of this indication, recruitment completed on time with 48% of subjects from EU.
  • Coordination: Effective coordination and problem-solving were crucial in overcoming these challenges.

 

Need help with your next dermatology or rheumatology study? Tell us a little about your needs.

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.